An open-label study evaluating the efficacy of abatacept in alopecia areata

J Am Acad Dermatol. 2021 Mar;84(3):841-844. doi: 10.1016/j.jaad.2020.09.091. Epub 2020 Oct 9.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Abatacept / administration & dosage*
  • Abatacept / adverse effects
  • Adolescent
  • Adult
  • Aged
  • Alopecia Areata / diagnosis
  • Alopecia Areata / drug therapy*
  • Alopecia Areata / immunology
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / administration & dosage*
  • Immune Checkpoint Inhibitors / adverse effects
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Substances

  • Immune Checkpoint Inhibitors
  • Abatacept